A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Merck Sharp & Dohme Corp.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01703208
First received: October 5, 2012
Last updated: October 22, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to evaluate the cardiovascular (CV) safety profile of MK-3102 in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with MK-3102 25 mg once weekly is non-inferior to treatment with placebo and active comparators across the MK-3102 program with regard to the risk of developing a confirmed event in the primary CV composite endpoint.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: MK-3102
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Time to first event in the cardiovascular (CV) composite endpoint of CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina requiring hospitalization [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in hemoglobin A1C (A1C) at Week 18 in a sub-study of participants taking insulin (with or without metformin) [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Percentage of participants who experienced at least one adverse event in a sub-study of participants taking insulin (with or without metformin) [ Time Frame: Up to Week 18 ] [ Designated as safety issue: Yes ]
  • Percentage of participants who discontinued from study drug due to an adverse event in a sub-study of participants taking insulin (with or without metformin) [ Time Frame: Up to Week 18 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Time to first composite CV endpoint of confirmed CV-related death, nonfatal MI, and nonfatal stroke [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: Yes ]
  • Time to first event for each of the individual CV endpoints: confirmed CV-related death, MI (fatal + nonfatal), stroke (fatal + nonfatal), and unstable angina requiring hospitalization [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: Yes ]
  • Time to all-cause mortality [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in A1C at Week 156 [ Time Frame: Baseline and Week 156 ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose (FPG) at Week 156 [ Time Frame: Baseline and Week 156 ] [ Designated as safety issue: No ]
  • Percentage of participants achieving a target A1C <7.0 % (53 mmol/mol) by Week 156 [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: No ]
  • Time to initiation of long-term insulin therapy (long-term insulin therapy is defined as a continuous period of insulin use of more than 3 months) in participants not receiving insulin at baseline [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in FPG at Week 18 in a sub-study of participants taking insulin (with or without metformin) [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Percentage of participants achieving a target A1C <7.0 % (53 mmol/mol) by Week 18 in a sub-study of participants taking insulin (with or without metformin) [ Time Frame: Up to 18 weeks ] [ Designated as safety issue: No ]
  • Percentage of participants who experienced at least one adverse event [ Time Frame: Up to 159 weeks ] [ Designated as safety issue: Yes ]
  • Percentage of participants who discontinued from study drug due to an adverse event [ Time Frame: Up to 156 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 4000
Study Start Date: October 2012
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK-3102
MK-3102 25 mg capsule administered orally once weekly
Drug: MK-3102
Placebo Comparator: Placebo
Matching placebo to MK-3102 capsule administered orally once weekly
Drug: Placebo

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with type 2 diabetes mellitus
  • Is on one of the following diabetes treatment regimens that is stable for at least 12 weeks (except for pioglitazone for at least 16 weeks) and is within the associated A1C range for that treatment regimen:

    1. A1C >= 6.5% and <= 10.0% (>=48 mmol/mol and <=86 mmol/mol) on: (a) diet or exercise alone (not on antihyperglycemic agent [AHA] for >= 12 weeks) OR (b) monotherapy with metformin (MF), pioglitazone (PIO) or an alpha-glucosidase inhibitor (AGI) or a sodium-glucose cotransporter inhibitor (SGLT2i) OR (c) dual combination therapy with MF, PIO, AGI or SGLT2i OR
    2. A1C >= 7.0% and <=10.0% (>=53 mmol/mol and <=86 mmol/mol) on (a) monotherapy with a sulfonylurea or meglitinide OR (b) dual combination therapy with a sulfonylurea or a meglitinide and MF, PIO, AGI, or SGLT2i OR
    3. A1C >=7.0% and <=10.0% (>=53 mmol/mol and <=86 mmol/mol) on one of the following insulin regimens (with or without metformin): (a) basal insulin (e.g.; insulin glargine, insulin detemir, NPH insulin, degludec) OR (b) prandial insulin (e.g. regular, aspart, lispro, glulisine) OR (c) basal/prandial insulin regimen consisting of multiple dose insulin injections of basal and prandial insulin or the use of pre-mixed insulin (e.g., Novolog 70/30®, Novolin 70/30®, Humalog 75/25®, or Humulin 70/30®
  • Pre-existing vascular disease (coronary artery disease, ischemic cerebrovascular disease, atherosclerotic peripheral artery disease)
  • (1) Male; (2) female not of reproductive potential; or (3) female of reproductive potential who agrees to remain abstinent or use alone or in conjunction with their partner 2 methods of contraception to prevent pregnancy during the study and for 21 days after the last dose of study drug.

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • Treated with rosiglitazone, a dipeptidyl peptidase-IV (DPP-4) inhibitor, or a glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior to study participation or previously treated with MK-3102
  • On a weight loss program and is not in the maintenance phase or has been on a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation
  • Medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Human immunodeficiency virus (HIV) as assessed by medical history
  • New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke, or transient ischemic neurological disorder within the past 3 months
  • History of malignancy <=5 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Clinically important hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Pregnant or breast feeding, or is expecting to conceive or donate eggs during the trial, including 21 days following the last dose of study drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01703208

Contacts
Contact: Toll Free Number 1-888-577-8839

  Hide Study Locations
Locations
United States, Alabama
Call for Information (Investigational Site 0108) Recruiting
Birmingham, Alabama, United States, 35233
Call for Information (Investigational Site 0194) Recruiting
Birmingham, Alabama, United States, 35211
United States, Arizona
Call for Information (Investigational Site 0013) Recruiting
Chandler, Arizona, United States, 85224
Call for Information (Investigational Site 0037) Recruiting
Gilbert, Arizona, United States, 85295
Call for Information (Investigational Site 0076) Recruiting
Phoenix, Arizona, United States, 85051
Call for Information (Investigational Site 0077) Recruiting
Tucson, Arizona, United States, 85724
Call for Information (Investigational Site 0004) Recruiting
Tucson, Arizona, United States, 85704
Call for Information (Investigational Site 0191) Recruiting
Tucson, Arizona, United States, 85710
United States, Arkansas
Call for Information (Investigational Site 0040) Recruiting
Hot Springs, Arkansas, United States, 71901
United States, California
Call for Information (Investigational Site 0053) Recruiting
Encinitas, California, United States, 92024
Call for Information (Investigational Site 0067) Recruiting
Fullerton, California, United States, 92835
Call for Information (Investigational Site 0088) Recruiting
Huntington Park, California, United States, 90255
Call for Information (Investigational Site 0179) Recruiting
Huntington Park, California, United States, 90255
Call for Information (Investigational Site 0189) Recruiting
Inglewood, California, United States, 90301
Call for Information (Investigational Site 0150) Recruiting
Lomita, California, United States, 90717
Call for Information (Investigational Site 0049) Recruiting
Los Angeles, California, United States, 90017
Call for Information (Investigational Site 0050) Recruiting
Los Angeles, California, United States, 90022
Call for Information (Investigational Site 0174) Recruiting
Los Angeles, California, United States, 90020
Call for Information (Investigational Site 0173) Recruiting
Northridge, California, United States, 91325
Call for Information (Investigational Site 0188) Recruiting
Orange, California, United States, 92866
Call for Information (Investigational Site 0065) Recruiting
Palm Springs, California, United States, 92262
Call for Information (Investigational Site 0085) Recruiting
Poway, California, United States, 92064
Call for Information (Investigational Site 0133) Recruiting
Redding, California, United States, 96001
Call for Information (Investigational Site 0026) Recruiting
Sacramento, California, United States, 95821
Call for Information (Investigational Site 0130) Recruiting
San Diego, California, United States, 92117
Call for Information (Investigational Site 0165) Recruiting
San Ramon, California, United States, 94582
Call for Information (Investigational Site 0139) Recruiting
Santa Monica, California, United States, 90404
Call for Information (Investigational Site 0170) Recruiting
Santa Rosa, California, United States, 95405
Call for Information (Investigational Site 0151) Recruiting
Simi Valley, California, United States, 93065
Call for Information (Investigational Site 0017) Recruiting
South Pasadena, California, United States, 91030
Call for Information (Investigational Site 0024) Recruiting
Tarzana, California, United States, 91356
Call for Information (Investigational Site 0153) Recruiting
Torrance, California, United States, 90502
Call for Information (Investigational Site 0086) Recruiting
Tustin, California, United States, 92780
United States, Colorado
Call for Information (Investigational Site 0168) Recruiting
Colorado Springs, Colorado, United States, 80918
United States, Delaware
Call for Information (Investigational Site 0069) Recruiting
Wilmington, Delaware, United States, 19803
United States, Florida
Call for Information (Investigational Site 0136) Recruiting
Boynton Beach, Florida, United States, 33472
Call for Information (Investigational Site 0093) Recruiting
Clearwater, Florida, United States, 33756
Call for Information (Investigational Site 0202) Recruiting
Fernandina Beach, Florida, United States, 32034
Call for Information (Investigational Site 0196) Recruiting
Fort Lauderdale, Florida, United States, 33308
Call for Information (Investigational Site 0043) Recruiting
Hallandale Beach, Florida, United States, 33009
Call for Information (Investigational Site 0039) Recruiting
Hialeah, Florida, United States, 33012
Call for Information (Investigational Site 0105) Recruiting
Hialeah, Florida, United States, 33015
Call for Information (Investigational Site 0115) Recruiting
Hialeah, Florida, United States, 33012
Call for Information (Investigational Site 0134) Recruiting
Lake Clarke Shores, Florida, United States, 33406
Call for Information (Investigational Site 0116) Recruiting
Lynn Haven, Florida, United States, 32444
Call for Information (Investigational Site 0183) Recruiting
Miami, Florida, United States, 33155
Call for Information (Investigational Site 0062) Recruiting
Miami, Florida, United States, 33165
Call for Information (Investigational Site 0201) Recruiting
Miami, Florida, United States, 33134
Call for Information (Investigational Site 0112) Recruiting
Miami, Florida, United States, 33175
Call for Information (Investigational Site 0008) Recruiting
Miami, Florida, United States, 33174
Call for Information (Investigational Site 0156) Recruiting
Miami, Florida, United States, 33136
Call for Information (Investigational Site 0195) Recruiting
Miami, Florida, United States, 33144
Call for Information (Investigational Site 0152) Recruiting
Miami, Florida, United States, 33126
Call for Information (Investigational Site 0005) Recruiting
Miami, Florida, United States, 33169
Call for Information (Investigational Site 0096) Recruiting
Miami, Florida, United States, 33155
Call for Information (Investigational Site 0010) Recruiting
Miami Lakes, Florida, United States, 33016
Call for Information (Investigational Site 0090) Recruiting
North Bay Village, Florida, United States, 33141
Call for Information (Investigational Site 0119) Recruiting
Orlando, Florida, United States, 32806
Call for Information (Investigational Site 0099) Recruiting
Orlando, Florida, United States, 32825
Call for Information (Investigational Site 0186) Recruiting
Palm Harbor, Florida, United States, 34684
Call for Information (Investigational Site 0199) Recruiting
Pembroke Pines, Florida, United States, 33029
Call for Information (Investigational Site 0158) Recruiting
Saint Petersburg, Florida, United States, 33713
Call for Information (Investigational Site 0140) Recruiting
South Miami, Florida, United States, 33143
Call for Information (Investigational Site 0056) Recruiting
Tampa, Florida, United States, 33606
Call for Information (Investigational Site 0200) Recruiting
Weston, Florida, United States, 33026
Call for Information (Investigational Site 0121) Recruiting
Winter Haven, Florida, United States, 33880
United States, Georgia
Call for Information (Investigational Site 0027) Recruiting
Atlanta, Georgia, United States, 30338
Call for Information (Investigational Site 0107) Recruiting
Atlanta, Georgia, United States, 30308
Call for Information (Investigational Site 0146) Recruiting
Atlanta, Georgia, United States, 30303
Call for Information (Investigational Site 0022) Recruiting
Columbus, Georgia, United States, 31904
Call for Information (Investigational Site 0046) Recruiting
Stockbridge, Georgia, United States, 30281
United States, Hawaii
Call for Information (Investigational Site 0052) Recruiting
Honolulu, Hawaii, United States, 96813
United States, Indiana
Call for Information (Investigational Site 0171) Recruiting
Bloomington, Indiana, United States, 47402
Call for Information (Investigational Site 0169) Recruiting
Franklin, Indiana, United States, 46131
Call for Information (Investigational Site 0175) Recruiting
Greenfield, Indiana, United States, 46140
Call for Information (Investigational Site 0185) Recruiting
Muncie, Indiana, United States, 47304
Call for Information (Investigational Site 0063) Recruiting
Valparaiso, Indiana, United States, 46383
United States, Iowa
Call for Information (Investigational Site 0060) Recruiting
Council Bluffs, Iowa, United States, 51501
United States, Louisiana
Call for Information (Investigational Site 0101) Recruiting
Covington, Louisiana, United States, 70433
Call for Information (Investigational Site 0157) Recruiting
Natchitoches, Louisiana, United States, 71457
Call for Information (Investigational Site 0190) Recruiting
Slidell, Louisiana, United States, 70458
United States, Maryland
Call for Information (Investigational Site 0145) Recruiting
Glenn Dale, Maryland, United States, 20769
Call for Information (Investigational Site 0045) Recruiting
Oxon Hill, Maryland, United States, 20745
United States, Massachusetts
Call for Information (Investigational Site 0123) Recruiting
Towson, Massachusetts, United States, 21204
United States, Michigan
Call for Information (Investigational Site 0054) Recruiting
Dearborn, Michigan, United States, 48124
Call for Information (Investigational Site 0002) Recruiting
Detroit, Michigan, United States, 48235
Call for Information (Investigational Site 0059) Recruiting
Kalamazoo, Michigan, United States, 49048
Call for Information (Investigational Site 0144) Recruiting
Rochester, Michigan, United States, 48307
United States, Mississippi
Call for Information (Investigational Site 0064) Recruiting
Olive Branch, Mississippi, United States, 38654
United States, Missouri
Call for Information (Investigational Site 0058) Recruiting
Kansas City, Missouri, United States, 64111
United States, Nebraska
Call for Information (Investigational Site 0072) Recruiting
Lincoln, Nebraska, United States, 68516
Call for Information (Investigational Site 0074) Recruiting
Omaha, Nebraska, United States, 68105
Call for Information (Investigational Site 0075) Recruiting
Omaha, Nebraska, United States, 68131
United States, New Hampshire
Call for Information (Investigational Site 0014) Recruiting
Nashua, New Hampshire, United States, 03063
United States, New Jersey
Call for Information (Investigational Site 0162) Recruiting
Bridgewater, New Jersey, United States, 08807-3060
Call for Information (Investigational Site 0203) Recruiting
Elizabeth, New Jersey, United States, 07201
Call for Information (Investigational Site 0001) Recruiting
Elizabeth, New Jersey, United States, 07202
Call for Information (Investigational Site 0147) Recruiting
Lodi, New Jersey, United States, 07644
United States, New York
Call for Information (Investigational Site 0021) Recruiting
Brooklyn, New York, United States, 11215
Call for Information (Investigational Site 0187) Recruiting
Hopewell Junction, New York, United States, 12533
Call for Information (Investigational Site 0117) Recruiting
New Windsor, New York, United States, 12553
Call for Information (Investigational Site 0020) Recruiting
New York, New York, United States, 11422
Call for Information (Investigational Site 0035) Recruiting
Staten Island, New York, United States, 10301
Call for Information (Investigational Site 0122) Recruiting
Syracuse, New York, United States, 13210
United States, North Carolina
Call for Information (Investigational Site 0038) Recruiting
Lenoir, North Carolina, United States, 28645
Call for Information (Investigational Site 0114) Recruiting
Shelby, North Carolina, United States, 28150
Call for Information (Investigational Site 0128) Recruiting
Wilmington, North Carolina, United States, 28401
United States, Ohio
Call for Information (Investigational Site 0172) Recruiting
Akron, Ohio, United States, 44313
Call for Information (Investigational Site 0073) Recruiting
Canal Fulton, Ohio, United States, 44614
Call for Information (Investigational Site 0007) Recruiting
Gallipolis, Ohio, United States, 45631
Call for Information (Investigational Site 0141) Recruiting
Marion, Ohio, United States, 43302
Call for Information (Investigational Site 0089) Recruiting
Toledo, Ohio, United States, 43623
United States, Oklahoma
Call for Information (Investigational Site 0018) Recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Call for Information (Investigational Site 0051) Recruiting
Downingtown, Pennsylvania, United States, 19335
Call for Information (Investigational Site 0078) Recruiting
Philadelphia, Pennsylvania, United States, 19104
Call for Information (Investigational Site 0184) Recruiting
Tipton, Pennsylvania, United States, 16684
United States, Rhode Island
Call for Information (Investigational Site 0161) Recruiting
East Greenhich, Rhode Island, United States
United States, South Carolina
Call for Information (Investigational Site 0160) Recruiting
Charleston, South Carolina, United States, 29407
Call for Information (Investigational Site 0061) Recruiting
Columbia, South Carolina, United States, 29204
Call for Information (Investigational Site 0132) Recruiting
Greer, South Carolina, United States, 29651
Call for Information (Investigational Site 0166) Recruiting
Manning, South Carolina, United States, 29102
Call for Information (Investigational Site 0042) Recruiting
Spartanburg, South Carolina, United States, 29303
Call for Information (Investigational Site 0044) Recruiting
Summerville, South Carolina, United States, 29485
United States, Tennessee
Call for Information (Investigational Site 0192) Recruiting
Bartlett, Tennessee, United States, 38133
Call for Information (Investigational Site 0081) Recruiting
Chattanooga, Tennessee, United States, 37404
Call for Information (Investigational Site 0167) Recruiting
Collierville, Tennessee, United States, 38017
Call for Information (Investigational Site 0033) Recruiting
Fayetteville, Tennessee, United States, 37334
Call for Information (Investigational Site 0180) Recruiting
Jackson, Tennessee, United States, 38305
Call for Information (Investigational Site 0181) Recruiting
Knoxville, Tennessee, United States, 37938
United States, Texas
Call for Information (Investigational Site 0084) Recruiting
Corpus Christi, Texas, United States, 78414
Call for Information (Investigational Site 0091) Recruiting
Dallas, Texas, United States, 75231
Call for Information (Investigational Site 0113) Recruiting
Dallas, Texas, United States, 75231
Call for Information (Investigational Site 0129) Recruiting
Dallas, Texas, United States, 75218
Call for Information (Investigational Site 0048) Recruiting
Dallas, Texas, United States, 75224
Call for Information (Investigational Site 0111) Recruiting
Houston, Texas, United States, 77004
Call for Information (Investigational Site 0083) Recruiting
Houston, Texas, United States, 77024
Call for Information (Investigational Site 0124) Recruiting
Houston, Texas, United States, 77081
Call for Information (Investigational Site 0071) Recruiting
Houston, Texas, United States, 77074
Call for Information (Investigational Site 0154) Recruiting
Houston, Texas, United States, 77027
Call for Information (Investigational Site 0047) Recruiting
Houston, Texas, United States, 77077
Call for Information (Investigational Site 0143) Recruiting
Houston, Texas, United States, 77095
Call for Information (Investigational Site 0016) Recruiting
Houston, Texas, United States, 77450
Call for Information (Investigational Site 0204) Recruiting
McKinney, Texas, United States, 75070
Call for Information (Investigational Site 0110) Recruiting
McKinney, Texas, United States, 75069
Call for Information (Investigational Site 0148) Recruiting
North Richland Hills, Texas, United States, 76180
Call for Information (Investigational Site 0023) Recruiting
San Antonio, Texas, United States, 78229
Call for Information (Investigational Site 0126) Recruiting
San Antonio, Texas, United States, 78229
Call for Information (Investigational Site 0095) Recruiting
San Marco, Texas, United States, 78667
Call for Information (Investigational Site 0098) Recruiting
Schertz, Texas, United States, 78154
Call for Information (Investigational Site 0159) Recruiting
Sugar Land, Texas, United States, 77479
Call for Information (Investigational Site 0131) Recruiting
Tomball, Texas, United States, 77375
Call for Information (Investigational Site 0149) Recruiting
Webster, Texas, United States, 77598
United States, Utah
Call for Information (Investigational Site 0137) Recruiting
Salt Lake City, Utah, United States, 84117
United States, Virginia
Call for Information (Investigational Site 0003) Recruiting
Manassas, Virginia, United States, 20110
Call for Information (Investigational Site 0036) Recruiting
Richmnond, Virginia, United States, 23220
Call for Information (Investigational Site 0142) Recruiting
Sterling, Virginia, United States, 20166
Call for Information (Investigational Site 0125) Recruiting
Virginia Beach, Virginia, United States, 23454
United States, Washington
Call for Information (Investigational Site 0155) Recruiting
Richland, Washington, United States, 99352
Call for Information (Investigational Site 0041) Recruiting
Spokane, Washington, United States, 99204
Argentina
Merck Sharp & Dohme (Argentina) Inc. Recruiting
Buenos Aires, Argentina
Contact: Alfredo Wilkinson    54 11 4796 8200      
Australia
Merck Sharp & Dohme Recruiting
North Ryde, Australia
Contact: Gary Jankelowitz    61 2 8988 8246      
Austria
MSD Osterreich GmbH Recruiting
Vienna, Austria
Contact: Karl Boegl    43 126044130      
Belgium
MSD Belgium BVBA/SPRL Recruiting
Brussels, Belgium
Contact: Frederik Tack    32 2 373 4324      
Brazil
MSD Brasil Recruiting
Sao Paulo, Brazil
Contact: Ricardo Germano    55 11 51897942      
Bulgaria
Merck Sharp & Dohme Bulgaria EOOD Recruiting
Sofia, Bulgaria
Contact: Eran Gefen    38 (044) 393 74 80      
Canada, Quebec
Merck Canada Recruiting
Kirkland, Quebec, Canada, H9H 3L1
Contact: Medical Information Centre / Centre de l'information medicale de Merck Canada    514-428-8600 / 1-800-567-2594      
Chile
Merck Sharp & Dohme (I.A.) Corp. Recruiting
Santiago, Chile
Contact: Maria Elena Azara Hernandez    56 2 6558958      
Colombia
MDS Colombia SAS Recruiting
Bogota, Colombia
Contact: Francesca Carvajal    57 1219109011090      
Croatia
Merck Sharp & Dohme d.o.o Recruiting
Zagreb, Croatia
Contact: Andina Hrabar    385 14878400      
Czech Republic
Merck Sharp and Dohme s.r.o. Recruiting
Praha, Czech Republic
Contact: Simona Martinkova    420 233010213      
Denmark
Merck Sharp & Dohme Recruiting
Glostrup, Denmark
Contact: Gert Andersen    45 44824475      
Finland
MSD Finland Oy Recruiting
Espoo, Finland
Contact: Kaisa Elomaa    358 20 7570300      
France
MSD France Recruiting
Paris, France
Contact: Dominique Blazy    33 147548990      
Georgia
Merck Sharp & Dohme IDEA, Inc. Recruiting
Tbilisi, Georgia
Contact: Eran Gefen    38 (044) 393 74 80      
Germany
Merck Sharp & Dohme GmbH Recruiting
Haar, Germany
Contact: German Medical Information Center    49 800 673 673 673      
Hong Kong
Merck Sharp & Dohme (Asia) Ltd. Recruiting
Hong Kong, Hong Kong
Contact: Lai Hung Jen    886 2 2730 0030      
Hungary
MSD Pharma Hungary Kft. Recruiting
Budapest, Hungary
Contact: Simona Martinkova    36 1 457 8522      
Israel
Merck Sharp & Dohme Co. Ltd. Recruiting
Hod Hasharon, Israel
Contact: Ofer Sharon    972 9 9539310      
Italy
MSD Italia S.r.l. Recruiting
Rome, Italy
Contact: Patrizia Nardini    39 06 361911      
Korea, Republic of
MSD Korea LTD Recruiting
Seoul, Korea, Republic of
Contact: Cem Ozesen    90 212 3361260      
Lebanon
MSD Idea, Inc. - LB BR Recruiting
Beirut, Lebanon
Contact: Amal Chalfoun    961 4542590      
Lithuania
UAB "Merck Sharp & Dohme" Recruiting
Vilnius, Lithuania
Contact: Andrius Bacevicius    370 52780243      
Malaysia
MSD Recruiting
Petaling Jaya, Malaysia
Contact: Boon Hock Yeoh    60 377181723      
Mexico
MSD Recruiting
Mexico City, Mexico
Contact: Juan Marques    52 55254819608      
Netherlands
Merck Sharp & Dohme BV Recruiting
Haarlem, Netherlands
Contact: Caroline Doornebos    31 23 515 3362      
New Zealand
Merck Sharp & Dohme (New Zealand) Ltd., Recruiting
Wellington, New Zealand
Contact: Gary Jankelowitz    61 2 8988 8246      
Philippines
Merck Sharp & Dohme (I.A.) Corporation Recruiting
Makati, Philippines
Contact: Cesar Recto    632 784 9500      
Poland
MSD Polska Sp. Z o.o. Recruiting
Warsaw, Poland
Contact: Adam Czernik    48 22 4784324      
Romania
Merck Sharp & Dohme Romania SRL Recruiting
Bucharest, Romania
Contact: Eran Gefen    38 (044) 393 74 80      
Russian Federation
Merck Sharp & Dohme IDEA, Inc. Recruiting
Moscow, Russian Federation
Contact: Maria Koroleva    7 0959410000      
Serbia
Merck Sharp & Dohme Recruiting
Belgrade, Serbia
Contact: Eran Gefen    38 (044) 393 74 80      
Slovakia
Merck Sharp Dohme S.R.O. Recruiting
Bratislava, Slovakia
Contact: Eva Kaszasova    420 233010213      
South Africa
MSD (Pty) LTD South Africa Recruiting
Midrand, South Africa
Contact: Khanyi Mzolo    27 11 655 3140      
Spain
Merck Sharp and Dohme de Espana S.A. Recruiting
Madrid, Spain
Contact: Cesar Sanz Rodriguez    34 913210600      
Sweden
MSD Recruiting
Sollentuna, Sweden
Contact: Tryggve Ljung    46 (0)70 545 28 66      
Taiwan
Merck Sharp & Dohme (I.A.) Corp. Recruiting
Taipei, Taiwan
Contact: Diana Zhang    886-2-66316030      
Ukraine
MSD Ukraine LLC Recruiting
Kiev, Ukraine
Contact: Eran Gefen    38 (044) 393 74 80      
United Kingdom
Merck Sharp & Dohme Ltd. Recruiting
Hoddesdon, United Kingdom
Contact: Paul Robinson    44 1992452396      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01703208     History of Changes
Other Study ID Numbers: 3102-018, 2012-002414-39
Study First Received: October 5, 2012
Last Updated: October 22, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 22, 2014